Evaluation of the colchicine tablet efficacy as an adjuvant therapy for patients with mild to moderate COVID-19

Evaluation of colchicine tablet efficacy as an adjuvant treatment for patients with mild to moderate COVID-19 in Qaem Hospital, Mashhad: A triple-blind randomized placebo controlled clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200408046990N2

Enrollment

Registered

2020-04-25

Start date

2020-04-29

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 pneumonia. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: one colchicine 1mg tablet daily for two weeks. Intervention 2: Control group: placebo with same appearance of colchicine tablet one daily for 2 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Clinical or laboratory diagnosis of mild to moderate covid-19 age between 18-85 y sign of written consent

Exclusion criteria

Exclusion criteria: use of protease inhibitors like kaletra history of allergy to colchicine pregnancy and lactation hepatic failure (child pugh C), kidney failure (GFR<30 ml/min), or heart failure with EF<40% concomitant use of CYP3A4 or pgp potent inhibitors or inducers concomitant use of statins except rosuvastatin active GI disturbances like active peptic ulcers transmission of patients to ICU ward or his/her intubation patients on colchicine for behcet disease or Mediterranean fever or gout patients with history of neuromuscular disease or chronic diarrhea or malabsorption

Design outcomes

Primary

Measure	Time frame
Fever. Timepoint: daily. Method of measurement: thermometer.;Clinical response to treatment (including improvement of cough, myalgia, headache, Olfactory and taste disorders). Timepoint: daily. Method of measurement: Based on patients examination and interview.;Radiologic response. Timepoint: two weeks after treatment. Method of measurement: lung CT scan.;Laboratory response. Timepoint: weekly. Method of measurement: assessment of serum level of CRP and CBC diff.;Drug adverse reaction. Timepoint: daily. Method of measurement: patient file and interview.	—

Measure

Time frame

Fever. Timepoint: daily. Method of measurement: thermometer.;Clinical response to treatment (including improvement of cough, myalgia, headache, Olfactory and taste disorders). Timepoint: daily. Method of measurement: Based on patients examination and interview.;Radiologic response. Timepoint: two weeks after treatment. Method of measurement: lung CT scan.;Laboratory response. Timepoint: weekly. Method of measurement: assessment of serum level of CRP and CBC diff.;Drug adverse reaction. Timepoint: daily. Method of measurement: patient file and interview.

—

Secondary

Measure	Time frame
Duration of hospitalization. Timepoint: end of the treatment. Method of measurement: patients' file.;Patients' clinical outcome. Timepoint: at the of the treatment. Method of measurement: patients' file.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSepideh Elyasi

Mashhad University of Medical Sciences

elyasis@mums.ac.ir+98 51 3180 1588

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 8, 2026